Ladenburg Thalmann Financial Services assumed coverage on shares of Calyxt (NASDAQ:CLXT) in a research note released on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $34.25 price objective on the stock.
Several other equities research analysts have also issued reports on CLXT. Citigroup lowered Calyxt from a buy rating to a neutral rating in a research report on Wednesday, September 27th. Wells Fargo & Company upped their price target on Calyxt from $17.00 to $30.00 and gave the company an outperform rating in a research report on Friday, September 29th. Zacks Investment Research lowered Calyxt from a hold rating to a sell rating in a research report on Monday, October 16th. BMO Capital Markets initiated coverage on Calyxt in a research report on Monday, October 30th. They issued an outperform rating and a $32.00 target price on the stock. Finally, Jefferies Group increased their target price on Calyxt to $27.00 and gave the stock a buy rating in a research report on Wednesday, November 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $29.05.
Calyxt (NASDAQ:CLXT) traded down $0.96 during mid-day trading on Wednesday, hitting $22.96. The company had a trading volume of 30,296 shares, compared to its average volume of 76,092. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.41 and a current ratio of 12.41. The firm has a market cap of $610.32 and a price-to-earnings ratio of -25.23. Calyxt has a twelve month low of $9.26 and a twelve month high of $31.89.
Calyxt, Inc is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics.
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.